Its great that we have another medication that helps people to lose weight as well as improving glycemic control.
Wegovy (semaglutide) is currently the most effective drug indicated for weight loss in the United States.
I think it is terrific for the field and for patients to have a second medication available.
Cristina Arias / Getty Images
When Ozempic is used this way, its considered off-label.
The company said it expects an FDA decision in late 2023.
What is being shown here is that Mounjaro is better for weight loss, even in people with diabetes.
This lowers blood sugar and makes people feel full for longer.
The study design is slightly different from clinical trial to clinical trial.
Lilly only just began a 700-person study, calledSURMOUNT-5, to test tirzepatide against semaglutide directly.
The data from the SURMOUNT-1 trial is very encouraging.
It looks great, Lau said.
But my recommendation is lets wait and see.
Lets not jump the gun and say tirzepatide will torpedo semaglutide because it showed better weight loss data.
Its also too soon to know how expensive and accessible Mounjaro will be as a weight loss medication.
Some insurance plans may cover obesity medications.
But most insurers, including Medicare dont.
Over time, it will help people see obesity as the chronic metabolic disease that it is.
In the meantime, ask a trusted provider about what treatment options are available to you for weight management.
